Patents by Inventor Karnail Singh

Karnail Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
    Publication number: 20240131141
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Inventors: Karnail Singh, Paul Spearman
  • VLP-based bivalent ebola vaccines and methods of making and using same
    Patent number: 11890337
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 6, 2024
    Assignee: Children's Hospital Medical Center
    Inventors: Karnail Singh, Paul Spearman
  • Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity
    Patent number: 11402380
    Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: Emory University
    Inventors: Paul Spearman, Karnail Singh, Xuemin Chen
  • VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
    Publication number: 20210386849
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Application
    Filed: August 25, 2021
    Publication date: December 16, 2021
    Inventors: Karnail Singh, Paul Spearman
  • VLP-based bivalent Ebola vaccines and methods of making and using same
    Patent number: 11129886
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 28, 2021
    Assignee: Children's Hospital Medical Center
    Inventors: Karnail Singh, Paul Spearman
  • VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
    Publication number: 20200085936
    Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 19, 2020
    Inventors: Karnail Singh, Paul Spearman
  • VLP-BASED MONOVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
    Publication number: 20200085937
    Abstract: Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 19, 2020
    Inventors: Xuemin Chen, Karnail Singh, Paul Spearman
  • Assays for Detecting Antibodies Capable of Mediating Antibody-Dependent Cell-Mediated Cytotoxicity
    Publication number: 20190227077
    Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 25, 2019
    Inventors: Paul Spearman, Karnail Singh, Xuemin Chen